SCHEMBL2335867

SCHEMBL2335867

c1ccc(C2(N3CCCC3)CCNCC2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 4/20 0.70
GRIN2A Q12879 4/20 0.70
GRIN2B Q13224 3/20 0.70
SIGMAR1 Q99720 2/20 0.70
GRIN2D O15399 1/20 0.70
GRIN3B O60391 1/20 0.70
CYP2B6 P20813 1/20 0.70
SLC6A2 P23975 1/20 0.70
SLC6A4 P31645 1/20 0.70
PRCP P42785 1/20 0.70
SLC6A3 Q01959 1/20 0.70
KCNH2 Q12809 1/20 0.70
GRIN2C Q14957 1/20 0.70
GRIN3A Q8TCU5 1/20 0.70
OPRM1 P35372 4/20 0.68
OPRD1 P41143 1/20 0.68
HTR2A P28223 1/20 0.44
OPRL1 P41146 2/20 0.43
SLC6A9 P48067 2/20 0.43
USP2 O75604 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6023084 0.98 GRIN1 (0.73) GRIN1GRIN2AGRIN2BSIGMAR1GRIN2D
Hydrochloric Acid SCHEMBL2333446 0.98 OPRM1 (0.71) GRIN1GRIN2AGRIN2BSIGMAR1GRIN2D
Hydrochloric Acid SCHEMBL7751676 0.96 OPRM1 (0.74) GRIN1GRIN2AGRIN2BSIGMAR1GRIN2D
Hydrochloric Acid SCHEMBL8365287 0.95 OPRM1 (0.72) GRIN1GRIN2AGRIN2BSIGMAR1GRIN2D
SCHEMBL2202714 0.90 GRIN1 (0.62) GRIN1GRIN2AGRIN2BSIGMAR1GRIN2D
SCHEMBL13333834 0.86 SIGMAR1 (0.57) GRIN1GRIN2AGRIN2BSIGMAR1GRIN2D
SCHEMBL19634059 0.86 GRIN1 (0.84) GRIN1GRIN2AGRIN2BSIGMAR1GRIN2D
SCHEMBL10261142 0.85 SIGMAR1 (0.58) GRIN1GRIN2AGRIN2BSIGMAR1GRIN2D
SCHEMBL4124756 0.84 SIGMAR1 (0.50) GRIN1GRIN2AGRIN2BSIGMAR1GRIN2D
SCHEMBL19262558 0.84 SIGMAR1 (0.50) GRIN1GRIN2AGRIN2BSIGMAR1GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206156-B2 Substituted indole derivatives Grünenthal GmbH (DE) 2015-12-08 US disclosed
CN-102015683-B The indole derivatives replaced GRUNENTHAL GMBH (DE) 2015-08-05 CN disclosed
EP-2254883-B1 SUBSTITUTED INDOLE DERIVATIVES GRUENENTHAL GMBH (DE) 2014-11-26 EP disclosed
US-20130116283-A1 Substituted indole derivatives Grünenthal GmbH (DE) 2013-05-09 US disclosed
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP disclosed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
EP-2356101-A1 PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN Grünenthal GmbH (DE) 2011-08-17 EP disclosed
EP-2254883-A1 SUBSTITUTED INDOLE DERIVATIVES Grünenthal GmbH (DE) 2010-12-01 EP disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed
WO-2010046109-A1 PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN Grünenthal GmbH (DE) 2010-04-29 WO disclosed
WO-2009103552-A1 SUBSTITUTED INDOLE DERIVATIVES Grünenthal GmbH (DE) 2009-08-27 WO disclosed
US-20090215828-A1 Substituted indole derivatives GRUNENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1268431-A1 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS Wyeth (US) 2003-01-02 EP disclosed
WO-2001072711-A1 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS WYETH (US) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215828-A1 Substituted indole derivatives IDO1, IDO2, TPH1 GRIN1 1858/4885GRIN2A 636/4885GRIN2B 1416/4885
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS GRIN1 2367/4885GRIN2A 1212/4885GRIN2B 454/4885
US-20130116283-A1 Substituted indole derivatives IDO1, IDO2, TPH1 GRIN1 1858/4885GRIN2A 636/4885GRIN2B 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.